Bibliography / References

1. www.MDVU.org, web site accessed 05/24/06
http://www.mdvu.org/library/disease/spasticity/
http://www.mdvu.org/library/disease/spasticity/spa_mtp.html http://www.mdvu.org/library/disease/spasticity/spa_mbtdm.html

2. Lance JW: Synopsis. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: Disordered Motor Control. Chicago: Year Book Medical Publishers. 1980: 480-485.

3. Sanger TD, Delgado MR, Gaebler-Spira, D, et al. Classification and Definition of Disorders Causing Hypertonia in Childhood. Pediatrics. 2003;111(1):89-97.

4. Rizzo M, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple Sclerosis 2004;10:589-595.

5. Francisco G, Boake C. Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. Arch Phys Med Rehabil 2003;84:1194-1199.

6. Meythaler J, Guin-Refroe S, Brunner, R Hadley M. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001;32:2099-2107.

7. Lioresal^® Intrathecal (baclofen injection) Drug Package Insert.

8. Gilmartin R, Bruce D, Storrs B, et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 2000;15:71-77.

9. Coffey R, Cahill D, Steers W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multi-center study. J Neurosurg 1993; 78:226-232.

10. Penn R., Intrathecal baclofen for spasticity of spinal origin: seven years experience. J Neurosurg 1992; 77:236-240.

11. Albright LA, Gilmartin R, Swift D, et al. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg 2003;98:291-295.

12. Campbell, WM, et al. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol 2002;44:660-665.

13. Middel B, et al. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997; 63(2): 204-209.

14. Albright LA, et al. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993;270(20):2475-2477.

15. Rawlins P. Intrathecal baclofen for spasticity of cerebral palsy: project coordination and nursing care. AJNN 1995;27(3):157-163.

16. Loubser PG, et al. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia 1991:29:48-64.

17. Parke B, et al. Functional outcome following delivery of intrathecal baclofen. Arch Phys Med Rehabil 1989;70:30-32.

18. Gooch JL, et al. Care provider assessment of intrathecal baclofen in children. Dev Med Child Neurol 2004;46:548-552.

19. Watkins CL, Leathley MJ, et al. Prevalence of spasticity post stroke. Clin Rehab 2002:16(5):515-22.

20. Ivanhoe CB, Francisco GE, McGuire JR, Subramanian T, Grissom SP. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil 2006;87(11):1509-1515

21. Schiess M et al. Functional motor improvement in stroke related spastic hemiparesis after intrathecal baclofen pump therapy. Neurology March 2006;S48.006 (abs).

22. Centers for Disease Control and Prevention, www.cdc.gov, web site accessed 05/24/06 http://www.cdc.gov/ncbddd/dd/cp2.htm

23. Meythaler JM, et al. Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents and adults with cerebral palsy. Arch Phys Med Rehabil 2001(82):155-161.

24. Koman LA, Paterson Smith B, eds. Management of Spasticity in Cerebral Palsy: The Role of Intrathecal Baclofen. Towson, MD: Data Trace Publishing Company; 2005.

25. Krach LE, et al. GMFM 1 year after continuous intrathecal baclofen infusion. Ped Rehabil 2005;8(3):207-213.

26. Krach LE, et al. Hip status in cerebral palsy after one year of continuous intrathecal baclofen infusion. Pediatric Neurology 2004;30(3):163-168.

27. Awaad Y et al. Functional assessment following intrathecal baclofen therapy in children with spastic cerebral palsy. J Child Neurol 2003;18(1):26-34.

28. Gerszten PC, Albright AL, Johnstone GF. Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. J Neurosurg 1998;88:1009-1013.

29. Stempien L, Tsai T. Intrathecal baclofen pump use for spasticity: a clinical survey. Am J Phys Med Rehabil 2000;79(6):536-541.

30. Albright LA. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996;11(2):77-83.

31. Van Schaeybroeck P, Nuttin B, Lieven L, Schrijvers E, Borghgraef C, Feys P. Intrathecal baclofen for intractable cerebral spasticity: a prospecitve placebo-controlled double-blind study. Neursurg 2000;46(3)603-612.

32. Ordia JI, et al. Continuous intrathecal baclofen infusion by a programmable pump in 131 consecutive patients with severe spasticity of spinal origin. Neuromod 2002;5(1):16-24.

33. Dario A, et al. Functional improvement in patients with severe spinal spasticity treated with chronic intrathecal baclofen infusion. Funct Neurol 2001;16:311-315.

34. Ordia JI, et al. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg. 1996;85:452-457.

35. Guillaume D, Van Havenbergh A, Vloeberghs M, Vidal J, Roeste G. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. Arch Phys Med Rehabil. 2005;86:2165-2171.

36. Sadiq SA, Wang GC Long-term intrathecal baclofen therapy in ambulatory patients with spasticity. J Neurol. 2006;253(5):563-9. Epub 2005 Nov.

37. Anson C, Shepherd C. Incidence of secondary complications in spinal cord injury. Int J Rehabil Research 1996;19:55-66.

38. Skold C, Levi R, Seiger A. Spasticity after traumatic spinal cord injury: nature, severity, and location. Arch Phys Med Rehabil. 1999;80:1548–1557.

39 UAB Model SCI System. Autonomic Dysreflexia Poster. Revised 1999. Available at: http://www.spinalcord.uab.edu.  Accessed July 17, 2006.

40. Korenkov AI, Niendorf WR, Darwish N, Glaeser E, Gaab MR.  Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries.  Neurosurg Rev. 2002;25:228-230.

41. Meythaler JM, McCary A, Hadley MN. Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. J Neurosurg. 1997;87:415-419.

42. Ordia JI, Fischer E, Adamski E, Spatz EL. Continuous intrathecal baclofen infusion delivered by a programmable pump for the treatment of severe spasticity following traumatic brain injury. Neuromod. 2002;5(2):103-107.

43. Becker R, Alberti O, Bauer BL. Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. J Neurol. 1997;244:160-166.

44. Francisco GE, Hu MM, Boake C, Ivanhoe CB. Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury. Brain Injury. 2005;19(5):359-364.

45. Ridley B. Intrathecal Baclofen Therapy: Challenges in patients with Multiple Sclerosis. Rehabil Nurs. 2006;31(4):158-164.

46. Krach LE, Nettleton A, Klempka B. Satisfaction of individuals treated long-term with continuous infusion of intrathecal baclofen by implanted programmable pump. Ped Rehabil 2006;9(3):210-218.

©Medtronic, Inc. 2008                                                   • Contact Medtronic • Privacy Statement • Terms of Use • Site Map